Petros Pharmaceuticals Inc (PTPI) - Total Assets
Based on the latest financial reports, Petros Pharmaceuticals Inc (PTPI) holds total assets worth $17.61 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Petros Pharmaceuticals Inc to assess how comfortably operating cash covers total debt obligations.
Petros Pharmaceuticals Inc - Total Assets Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Petros Pharmaceuticals Inc for net asset value and shareholders' equity analysis.
Petros Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Petros Pharmaceuticals Inc's total assets of $17.61 Million consist of 68.6% current assets and 31.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 34.9% |
| Accounts Receivable | $416.08K | 3.9% |
| Inventory | $1.35 Million | 12.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $3.20 Million | 30.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2024)
This chart illustrates how Petros Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Petros Pharmaceuticals Inc (PTPI) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Petros Pharmaceuticals Inc's current assets represent 68.6% of total assets in 2024, an increase from 23.6% in 2018.
- Cash Position: Cash and equivalents constituted 34.9% of total assets in 2024, up from 4.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 30.0% of total assets, a decrease from 68.0% in 2018.
- Asset Diversification: The largest asset category is intangible assets at 30.1% of total assets.
Petros Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Petros Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Livzon Pharmaceutical Group Inc
SHE:000513
|
China | CN¥24.19 Billion |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321
|
China | CN¥3.63 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Hunan Warrant Pharmaceutical Co. Ltd. A
SHG:688799
|
China | CN¥2.53 Billion |
|
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
|
China | CN¥6.56 Billion |
|
Jianmin Pharmaceutical Group Co Ltd
SHG:600976
|
China | CN¥4.69 Billion |
|
Canopy Growth Corp
TO:WEED
|
Canada | CA$1.11 Billion |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
Germany | €125.48 Million |
Petros Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.53 | 1.60 | 0.13 |
| Quick Ratio | 0.53 | 1.46 | 0.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-12.67 Million | $6.68 Million | $-44.83 Million |
Petros Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Petros Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.45 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -68.5% |
| Total Assets | $10.64 Million |
| Market Capitalization | $101.47K USD |
Valuation Analysis
Below Book Valuation: The market values Petros Pharmaceuticals Inc's assets below their book value (0.01x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Petros Pharmaceuticals Inc's assets decreased by 68.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Petros Pharmaceuticals Inc (2018–2024)
The table below shows the annual total assets of Petros Pharmaceuticals Inc from 2018 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $10.64 Million | -68.53% |
| 2023-12-31 | $33.80 Million | +4.24% |
| 2022-12-31 | $32.42 Million | -51.89% |
| 2021-12-31 | $67.39 Million | -3.53% |
| 2020-12-31 | $69.85 Million | +19.68% |
| 2019-12-31 | $58.37 Million | -12.74% |
| 2018-12-31 | $66.89 Million | -- |
About Petros Pharmaceuticals Inc
Petros Pharmaceuticals, Inc., a healthcare technology company, focuses on developing and licensing proprietary SaaS platform and Software as a medical device web application designed to assist pharmaceutical companies. The company is based in New York, New York.